The DOI matches its Crossref record; 124 of the 124 references it cites were found in a registry or an index.
Diagnosis and treatment of Parkinson disease: molecules to medicine
Open accessAbstract
Parkinson disease (PD) is a chronic, progressive neurodegenerative disorder that affects at least 1% of people by age 70 (1-3).James Parkinson provided the first detailed description of the disease in his 1817 monograph "An Essay on the Shaking Palsy."In the latter part of the nineteenth century, Charcot further refined the description of this disorder and identified the cardinal clinical features of PD including rest tremor, rigidity, balance impairment, and slowness of movement (reviewed in ref. 4).An early clue to the pathology of the disease came from Brissaud, who speculated that damage in the substantia nigra (SN) might lead to PD (5, 6).Eosinophilic inclusions (Lewy bodies) later were identified in the brains of PD patients (7) and, along with abnormalities in the SN, became a recognized pathologic marker of the disease (8).A major advance in the understanding of PD came when dopamine deficiency was discovered in the corpus striatum and SN of brains taken from patients (9).Later studies demonstrated the connection between the SN and the striatum, thus suggesting that dopaminergic cell loss in the SN directly leads to dopaminergic deficiency in the striatum (10).The determination that PD is a disease of dopamine loss led to the development of ratio-nal therapies aimed at correcting this deficiency (11).After some initial uncertainty, the dopamine precursor levodopa proved to be a powerful PD treatment (12).Subsequent advances in therapy included combining levodopa with a peripheral decarboxylase inhibitor, such as carbidopa or benserazide (13, 14).This combination significantly reduced the nausea and vomiting associated with levodopa therapy and allowed a greater proportion of levodopa to enter the brain.Similarly, catechol-O-methyltransferase (COMT) inhibitors, which prolong the half-life of levodopa and dopamine were found to enhance the effect of a given levodopa dose (15-17).In addition to increasing the level of dopamine precursors, the focus of therapeutic design was also on limiting the breakdown of endogenous dopamine.The monoamine oxidase type B (MAO-B) inhibitor selegiline works in this fashion and provides symptomatic benefit (18).Finally, the development of dopamine agonists that directly stimulate postsynaptic dopamine receptors, thus bypassing dopamine synthesis completely, further illustrates how novel therapies can be borne from knowledge of pathology (19,20).Surgical therapies that reduce tremor and rigidity in PD patients were used prior to the advent of levodopa treatment.Meyers pioneered surgical lesioning procedures that targeted symptoms and spared patients from the hemiparesis that resulted from earlier surgical approaches.These procedures largely were abandoned once levodopa therapy became more common (21).Recent advances in the understanding of basal ganglia physiology and the development of new technologies has led to a reemergence of surgical PD therapies in the form of deep brain stimulation (DBS) (22,23).DBS has become increasingly common in patients whose disease is difficult to manage with medical therapy alone.Despite these landmark advances in symptomatic PD therapy, the ability of these treatments to facilitate an acceptable quality of life for the patient wanes with time.This is due to the development of motor complications including wearing-off (the Diagnosis and treatment of Parkinson disease: molecules to medicine
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Staging of brain pathology related to sporadic Parkinson’s disease
Braak, H., Tredici, K. D., Rüb, U., de Vos, R. A. I., Jansen Steur, E. N. H., & Braak, E. (2003) · Neurobiology of Aging · doi:10.1016/s0197-4580(02)00065-9 · Cited by 10,777
Hughes, A. J., Daniel, S. E., Kilford, L., & Lees, A. J. (1992) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.55.3.181 · Cited by 10,378
Spillantini, M. G., Schmidt, M. L., Lee, V. M.-Y., Trojanowski, J. Q., Jakes, R., & Goedert, M. (1997) · Nature · doi:10.1038/42166 · Cited by 8,382
Mutation in the α-Synuclein Gene Identified in Families with Parkinson's Disease
Polymeropoulos, M. H., Lavedan, C., Leroy, E., Ide, S. E., Dehejia, A., Dutra, A., Pike, B., Root, H., Rubenstein, J., Boyer, R., et al. (1997) · Science · doi:10.1126/science.276.5321.2045 · Cited by 8,240
Mutations in the parkin gene cause autosomal recessive juvenile parkinsonism
Kitada, T., Asakawa, S., Hattori, N., Matsumine, H., Yamamura, Y., Minoshima, S., Yokochi, M., Mizuno, Y., & Shimizu, N. (1998) · Nature · doi:10.1038/33416 · Cited by 5,227
Chronic Parkinsonism in Humans Due to a Product of Meperidine-Analog Synthesis
Langston, J. W., Ballard, P., Tetrud, J. W., & Irwin, I. (1983) · Science · doi:10.1126/science.6823561 · Cited by 4,914
α-Synuclein Locus Triplication Causes Parkinson's Disease
Singleton, A. B., Farrer, M., Johnson, J., Singleton, A., Hague, S., Kachergus, J., Hulihan, M., Peuralinna, T., Dutra, A., Nussbaum, R., et al. (2003) · Science · doi:10.1126/science.1090278 · Cited by 4,383
AlaSOPro mutation in the gene encoding α-synuclein in Parkinson's disease
Krüger, R., Kuhn, W., Müller, T., Woitalla, D., Graeber, M., Kösel, S., Przuntek, H., Epplen, J. T., Schols, L., & Riess, O. (1998) · Nature Genetics · doi:10.1038/ng0298-106 · Cited by 3,836
Chronic systemic pesticide exposure reproduces features of Parkinson's disease
Betarbet, R., Sherer, T. B., MacKenzie, G., Garcia-Osuna, M., Panov, A. V., & Greenamyre, J. T. (2000) · Nature Neuroscience · doi:10.1038/81834 · Cited by 3,683
Frequency Dependence of Signal Power and Spatial Reach of the Local Field Potential
Leski, S., Lindén, H., Tetzlaff, T., Pettersen, K. H., & Einevoll, G. T. (2013) · PubMed · doi:10.18154/rwth-conv-084442 · Cited by 3,639
Hereditary Early-Onset Parkinson's Disease Caused by Mutations in PINK1
Valente, E. M., Abou-Sleiman, P. M., Caputo, V., Muqit, M. M. K., Harvey, K., Gispert, S., Ali, Z., Del Turco, D., Bentivoglio, A. R., Healy, D. G., et al. (2004) · Science · doi:10.1126/science.1096284 · Cited by 3,481
Journal of Biological Chemistry
(2021) · Journal of Biological Chemistry · doi:10.1074/jbc · Cited by 3,400
Spillantini, M. G., Crowther, R. A., Jakes, R., Hasegawa, M., & Goedert, M. (1998) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.95.11.6469 · Cited by 2,868
Mutations in the DJ-1 Gene Associated with Autosomal Recessive Early-Onset Parkinsonism
Bonifati, V., Rizzu, P., van Baren, M. J., Schaap, O., Breedveld, G. J., Krieger, E., Dekker, M. C. J., Squitieri, F., Ibanez, P., Joosse, M., et al. (2003) · Science · doi:10.1126/science.1077209 · Cited by 2,778
The new mutation, E46K, of α‐synuclein causes parkinson and Lewy body dementia
Zarranz, J. J., Alegre, J., Gómez‐Esteban, J. C., Lezcano, E., Ros, R., Ampuero, I., Vidal, L., Hoenicka, J., Rodriguez, O., Atarés, B., et al. (2004) · Annals of Neurology · doi:10.1002/ana.10795 · Cited by 2,737
Burns, R. S., Chiueh, C. C., Markey, S. P., Ebert, M. H., Jacobowitz, D. M., & Kopin, I. J. (1983) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.80.14.4546 · Cited by 2,149
Impaired Degradation of Mutant α-Synuclein by Chaperone-Mediated Autophagy
Cuervo, A. M., Stefanis, L., Fredenburg, R., Lansbury, P. T., & Sulzer, D. (2004) · Science · doi:10.1126/science.1101738 · Cited by 2,024
Reversal of Experimental Parkinsonism by Lesions of the Subthalamic Nucleus
Bergman, H., Wichmann, T., & DeLong, M. R. (1990) · Science · doi:10.1126/science.2402638 · Cited by 1,907
Ehringer, H., & Hornykiewicz, O. (1960) · Klinische Wochenschrift · doi:10.1007/bf01485901 · Cited by 1,867
Mice Lacking α-Synuclein Display Functional Deficits in the Nigrostriatal Dopamine System
Abeliovich, A., Schmitz, Y., Fariñas, I., Choi-Lundberg, D., Ho, W.-H., Castillo, P. E., Shinsky, N., Verdugo, J. M. G., Armanini, M., Ryan, A., et al. (2000) · Neuron · doi:10.1016/s0896-6273(00)80886-7 · Cited by 1,722
The ubiquitin pathway in Parkinson's disease
Leroy, E., Boyer, R., Auburger, G., Leube, B., Ulm, G., Mezey, E., Harta, G., Brownstein, M. J., Jonnalagada, S., Chernova, T., et al. (1998) · Nature · doi:10.1038/26652 · Cited by 1,571
NACP, A Protein Implicated in Alzheimer's Disease and Learning, Is Natively Unfolded
Weinreb, P. H., Zhen, W., Poon, A. W., Conway, K. A., & Lansbury, P. T. (1996) · Biochemistry · doi:10.1021/bi961799n · Cited by 1,523
Association between Early-Onset Parkinson's Disease and Mutations in the Parkin Gene
Lücking, C. B., Dürr, A., Bonifati, V., Vaughan, J., De Michele, G., Gasser, T., Harhangi, B. S., Meco, G., Denèfle, P., Wood, N. W., et al. (2000) · New England Journal of Medicine · doi:10.1056/nejm200005253422103 · Cited by 1,433
α-Synuclein Is Degraded by Both Autophagy and the Proteasome
Webb, J. L., Ravikumar, B., Atkins, J., Skepper, J. N., & Rubinsztein, D. C. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m300227200 · Cited by 1,429
Braak, H., de Vos, R. A. I., Bohl, J., & Del Tredici, K. (2006) · Neuroscience Letters · doi:10.1016/j.neulet.2005.11.012 · Cited by 1,354
Modification of Parkinsonism — Chronic Treatment with L-Dopa
Cotzias, G. C., Papavasiliou, P. S., & Gellene, R. (1969) · New England Journal of Medicine · doi:10.1056/nejm196902132800701 · Cited by 1,284
MOLECULAR PATHOPHYSIOLOGY OF PARKINSON'S DISEASE
Moore, D. J., West, A. B., Dawson, V. L., & Dawson, T. M. (2005) · Annual Review of Neuroscience · doi:10.1146/annurev.neuro.28.061604.135718 · Cited by 1,280
3,4-Dihydroxyphenylalanine and 5-Hydroxytryptophan as Reserpine Antagonists
CARLSSON, A., LINDQVIST, M., & MAGNUSSON, T. (1957) · Nature · doi:10.1038/1801200a0 · Cited by 1,278
Zhang, Y., Gao, J., Chung, K. K. K., Huang, H., Dawson, V. L., & Dawson, T. M. (2000) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.240347797 · Cited by 982
α-Synuclein Cooperates with CSPα in Preventing Neurodegeneration
Chandra, S., Gallardo, G., Fernández-Chacón, R., Schlüter, O. M., & Südhof, T. C. (2005) · Cell · doi:10.1016/j.cell.2005.09.028 · Cited by 966
A Clinicopathologic Study of 100 Cases of Parkinson's Disease
Hughes, A. J., Daniel, S. E., Blankson, S., & Lees, A. J. (1993) · Archives of Neurology · doi:10.1001/archneur.1993.00540020018011 · Cited by 956
Expanding insights of mitochondrial dysfunction in Parkinson's disease
Abou-Sleiman, P. M., Muqit, M. M. K., & Wood, N. W. (2006) · Nature Reviews Neuroscience · doi:10.1038/nrn1868 · Cited by 869
Improved accuracy of clinical diagnosis of Lewy body Parkinson’s disease
Hughes, A. J., Daniel, S. E., & Lees, A. J. (2001) · Neurology · doi:10.1212/wnl.57.8.1497 · Cited by 807
Liu, Y., Fallon, L., Lashuel, H. A., Liu, Z., & Lansbury, P. T. (2002) · Cell · doi:10.1016/s0092-8674(02)01012-7 · Cited by 785
S -Nitrosylation of Parkin Regulates Ubiquitination and Compromises Parkin's Protective Function
Chung, K. K. K., Thomas, B., Li, X., Pletnikova, O., Troncoso, J. C., Marsh, L., Dawson, V. L., & Dawson, T. M. (2004) · Science · doi:10.1126/science.1093891 · Cited by 769
Brodie, S. E. (1996) · Survey of Ophthalmology · doi:10.1016/s0039-6257(96)80075-0 · Cited by 745
Idiopathic hyposmia as a preclinical sign of Parkinson's disease
Ponsen, M. M., Stoffers, D., Booij, J., van Eck‐Smit, B. L. F., Wolters, E. C., & Berendse, H. W. (2004) · Annals of Neurology · doi:10.1002/ana.20160 · Cited by 740
Dopamine covalently modifies and functionally inactivates parkin
LaVoie, M. J., Ostaszewski, B. L., Weihofen, A., Schlossmacher, M. G., & Selkoe, D. J. (2005) · Nature Medicine · doi:10.1038/nm1314 · Cited by 722
El‐Agnaf, O. M. A., Salem, S. A., Paleologou, K. E., Curran, M. D., Gibson, M. J., Court, J. A., Schlossmacher, M. G., & Allsop, D. (2006) · The FASEB Journal · doi:10.1096/fj.03-1449com · Cited by 715
Kim, R. H., Smith, P. D., Aleyasin, H., Hayley, S., Mount, M. P., Pownall, S., Wakeham, A., You-Ten, A. J., Kalia, S. K., Horne, P., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0501282102 · Cited by 701
Lewandowsky, M. (1912) · The Journal of Nervous and Mental Disease · doi:10.1097/00005053-191206000-00015 · Cited by 689
LRRK2 G2019S as a Cause of Parkinson's Disease in Ashkenazi Jews
Ozelius, L. J., Senthil, G., Saunders-Pullman, R., Ohmann, E., Deligtisch, A., Tagliati, M., Hunt, A. L., Klein, C., Henick, B., Hailpern, S. M., et al. (2006) · New England Journal of Medicine · doi:10.1056/nejmc055509 · Cited by 665
Proteasomal function is impaired in substantia nigra in Parkinson’s disease
McNaught, K. S. P., & Jenner, P. (2001) · Neuroscience Letters · doi:10.1016/s0304-3940(00)01701-8 · Cited by 653
(2004) · doi:10.1002/ana.10846 · Cited by 614
Accuracy of Clinical Diagnosis in Parkinsonism — A Prospective Study
Rajput, A. H., Rozdilsky, B., & Rajput, A. (1991) · Canadian Journal of Neurological Sciences / Journal Canadien des Sciences Neurologiques · doi:10.1017/s0317167100031814 · Cited by 596
Resistance of α-synuclein null mice to the parkinsonian neurotoxin MPTP
Dauer, W., Kholodilov, N., Vila, M., Trillat, A.-C., Goodchild, R., Larsen, K. E., Staal, R., Tieu, K., Schmitz, Y., Yuan, C. A., et al. (2002) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.172514599 · Cited by 581
Altered proteasomal function in sporadic Parkinson’s disease
St. P. McNaught, K., Belizaire, R., Isacson, O., Jenner, P., & Olanow, C. W. (2003) · Experimental Neurology · doi:10.1006/exnr.2002.8050 · Cited by 573
Systemic exposure to proteasome inhibitors causes a progressive model of Parkinson's disease
McNaught, K. S. P., Perl, D. P., Brownell, A., & Olanow, C. W. (2004) · Annals of Neurology · doi:10.1002/ana.20186 · Cited by 548
de Rijk, M. C., Launer, L. J., Berger, K., Breteler, M. M. B., Dartigues, J. F., Baldereschi, M., Fratiglioni, L., Lobo, A., Martinez-Lage, J., Trenkwalder, C., et al. (2000) · PubMed · Cited by 528
Prevalence of Parkinson's disease in Europe : A collaborative study of population-based cohorts
de Rijk, M. C., Launer, L. J., Berger, K., Breteler, M. M. B., Dartigues, J. F., Baldereschi, M., Fratiglioni, L., Lobo, A., Martínez‐Lage, J. M., Trenkwalder, C., et al. (2000) · EUR Research Repository (Erasmus University Rotterdam) · Cited by 514
High-Resolution Whole-Genome Association Study of Parkinson Disease
Maraganore, D. M., de Andrade, M., Lesnick, T. G., Strain, K. J., Farrer, M. J., Rocca, W. A., Pant, P. V. K., Frazer, K. A., Cox, D. R., & Ballinger, D. G. (2005) · The American Journal of Human Genetics · doi:10.1086/496902 · Cited by 508
PINK1 mutations are associated with sporadic early‐onset parkinsonism
Valente, E. M., Salvi, S., Ialongo, T., Marongiu, R., Elia, A. E., Caputo, V., Romito, L., Albanese, A., Dallapiccola, B., & Bentivoglio, A. R. (2004) · Annals of Neurology · doi:10.1002/ana.20256 · Cited by 505
THE BRAIN-STEM LESIONS IN PARKINSONISM
Greenfield, J. G., & Bosanquet, F. D. (1953) · Journal of Neurology, Neurosurgery & Psychiatry · doi:10.1136/jnnp.16.4.213 · Cited by 494
LRRK2 G2019S as a Cause of Parkinson's Disease in North African Arabs
Lesage, S., Dürr, A., Tazir, M., Lohmann, E., Leutenegger, A.-L., Janin, S., Pollak, P., & Brice, A. (2006) · New England Journal of Medicine · doi:10.1056/nejmc055540 · Cited by 494
Mutations in NR4A2 associated with familial Parkinson disease
Le, W.-D., Xu, P., Jankovic, J., Jiang, H., Appel, S. H., Smith, R. G., & Vassilatis, D. K. (2003) · Nature Genetics · doi:10.1038/ng1066 · Cited by 487
Lewy bodies and parkinsonism in families with parkin mutations
Farrer, M., Chan, P., Chen, R., Tan, L., Lincoln, S., Hernandez, D., Forno, L., Gwinn‐Hardy, K., Petrucelli, L., Hussey, J., et al. (2001) · Annals of Neurology · doi:10.1002/ana.1132 · Cited by 485
Oxidative Damage of DJ-1 Is Linked to Sporadic Parkinson and Alzheimer Diseases
Choi, J., Sullards, M. C., Olzmann, J. A., Rees, H. D., Weintraub, S. T., Bostwick, D. E., Gearing, M., Levey, A. I., Chin, L.-S., & Li, L. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m509079200 · Cited by 483
Li, W., West, N., Colla, E., Pletnikova, O., Troncoso, J. C., Marsh, L., Dawson, T. M., Jäkälä, P., Hartmann, T., Price, D. L., et al. (2005) · Proceedings of the National Academy of Sciences · doi:10.1073/pnas.0406976102 · Cited by 472
Phosphorylated α-Synuclein Is Ubiquitinated in α-Synucleinopathy Lesions
Hasegawa, M., Fujiwara, H., Nonaka, T., Wakabayashi, K., Takahashi, H., Lee, V. M.-Y., Trojanowski, J. Q., Mann, D., & Iwatsubo, T. (2002) · Journal of Biological Chemistry · doi:10.1074/jbc.m208046200 · Cited by 428
Zhang, L., Shimoji, M., Thomas, B., Moore, D. J., Yu, S.-W., Marupudi, N. I., Torp, R., Torgner, I. A., Ottersen, O. P., Dawson, T. M., et al. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi211 · Cited by 421
Snyder, H., Mensah, K., Theisler, C., Lee, J., Matouschek, A., & Wolozin, B. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m208641200 · Cited by 420
Risk tables for parkinsonism and Parkinson’s disease
Elbaz, A., Bower, J. H., Maraganore, D. M., McDonnell, S. K., Peterson, B. J., Ahlskog, J. E., Schaid, D. J., & Rocca, W. A. (2002) · Journal of Clinical Epidemiology · doi:10.1016/s0895-4356(01)00425-5 · Cited by 377
Pathologic and biochemical studies of juvenile parkinsonism linked to chromosome 6q
Mori, H., Kondo, T., Yokochi, M., Matsumine, H., Nakagawa-Hattori, Y., Miyake, T., Suda, K., & Mizuno, Y. (1998) · Neurology · doi:10.1212/wnl.51.3.890 · Cited by 370
Early Environmental Origins of Neurodegenerative Disease in Later Life
Landrigan, P. J., Sonawane, B., Butler, R. N., Trasande, L., Callan, R., & Droller, D. (2005) · Environmental Health Perspectives · doi:10.1289/ehp.7571 · Cited by 357
The Oxidation State of DJ-1 Regulates its Chaperone Activity Toward α-Synuclein
Zhou, W., Zhu, M., Wilson, M. A., Petsko, G. A., & Fink, A. L. (2006) · Journal of Molecular Biology · doi:10.1016/j.jmb.2005.12.030 · Cited by 350
Spira, P. J., Sharpe, D. M., Halliday, G. M., Cavanagh, J., & Nicholson, G. A. (2001) · PubMed · Cited by 343
INFLUENCE OF THE SUBSTANTIA NIGRA ON THE CATECHOLAMINE CONTENT OF THE STRIATUM
POIRIER, L. J., & SOURKES, T. L. (1965) · Brain · doi:10.1093/brain/88.1.181 · Cited by 339
Diagnosis and Initial Management of Parkinson's Disease
Nutt, J. G., & Wooten, G. F. (2005) · New England Journal of Medicine · doi:10.1056/nejmcp043908 · Cited by 338
Clinical heterogeneity of α‐synuclein gene duplication in Parkinson's disease
Nishioka, K., Hayashi, S., Farrer, M. J., Singleton, A. B., Yoshino, H., Imai, H., Kitami, T., Sato, K., Kuroda, R., Tomiyama, H., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20753 · Cited by 316
How much phenotypic variation can be attributed to parkin genotype?
Lohmann, E., Periquet, M., Bonifati, V., Wood, N. W., De Michele, G., Bonnet, A., Fraix, V., Broussolle, E., Horstink, M. W. I. M., Vidailhet, M., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10613 · Cited by 301
Suchowersky, O., Reich, S., Perlmutter, J., Zesiewicz, T., Gronseth, G., & Weiner, W. J. (2006) · Neurology · doi:10.1212/01.wnl.0000215437.80053.d0 · Cited by 280
Handbook of Parkinson's Disease
(2013) · CRC Press eBooks · doi:10.1201/b14361 · Cited by 272
UCHL1 is a Parkinson's disease susceptibility gene
Maraganore, D. M., Lesnick, T. G., Elbaz, A., Chartier‐Harlin, M., Gasser, T., Krüger, R., Hattori, N., Mellick, G. D., Quattrone, A., Satoh, J., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20017 · Cited by 262
Parkinson's disease : diagnosis and clinical management
Factor, S. A., & Weiner, W. J. (2002) · Cited by 254
Ko, H. S., von Coelln, R., Sriram, S. R., Kim, S. W., Chung, K. K. K., Pletnikova, O., Troncoso, J., Johnson, B., Saffary, R., Goh, E. L., et al. (2005) · The Journal of Neuroscience · doi:10.1523/jneurosci.2172-05.2005 · Cited by 247
Association of DJ-1 and parkin mediated by pathogenic DJ-1 mutations and oxidative stress
Moore, D. J., Zhang, L., Troncoso, J., Lee, M. K., Hattori, N., Mizuno, Y., Dawson, T. M., & Dawson, V. L. (2005) · Human Molecular Genetics · doi:10.1093/hmg/ddi007 · Cited by 245
Parkin mutations and susceptibility alleles in late‐onset Parkinson's disease
Oliveira, S. A., Scott, W. K., Martin, E. R., Nance, M. A., Watts, R. L., Hubble, J. P., Koller, W. C., Pahwa, R., Stern, M. B., Hiner, B. C., et al. (2003) · Annals of Neurology · doi:10.1002/ana.10524 · Cited by 214
α‐Synuclein promoter confers susceptibility to Parkinson's disease
Pals, P., Lincoln, S., Manning, J., Heckman, M., Skipper, L., Hulihan, M., Van den Broeck, M., De Pooter, T., Cras, P., Crook, J., et al. (2004) · Annals of Neurology · doi:10.1002/ana.20268 · Cited by 212
Paralysis agitans. I. Pathologische Anatomie
Lewy, F. (1912) · Medical Entomology and Zoology · Cited by 208
Mizuta, I., Satake, W., Nakabayashi, Y., Ito, C., Suzuki, S., Momose, Y., Nagai, Y., Oka, A., Inoko, H., Fukae, J., et al. (2006) · Human Molecular Genetics · doi:10.1093/hmg/ddl030 · Cited by 207
Hereditary form of parkinsonism—dementia
Muenter, M. D., Forno, L. S., Hornykiewicz, O., Kish, S. J., Maraganore, D. M., Caselli, R. J., Okazaki, H., Howard, F. M., Snow, B. J., & Calne, D. B. (1998) · Annals of Neurology · doi:10.1002/ana.410430612 · Cited by 201
Rochet, J.-C., Outeiro, T. F., Conway, K. A., Ding, T. T., Volles, M. J., Lashuel, H. A., Bieganski, R. M., Lindquist, S. L., & Lansbury, P. T. (2004) · Journal of Molecular Neuroscience · doi:10.1385/jmn:23:1-2:023 · Cited by 191
Biomarkers and Parkinson's disease
Michell, A. W. (2004) · Brain · doi:10.1093/brain/awh198 · Cited by 183
Mutational analysis of the PINK1 gene in early-onset parkinsonism in Europe and North Africa
Ibáñez, P., Lesage, S., Lohmann, E., Thobois, S., Michele, G. D., Borg, M., Agid, Y., Dürr, A., & Brice, A. (2006) · Brain · doi:10.1093/brain/awl005 · Cited by 182
Lim, K., Dawson, V. L., & Dawson, T. M. (2005) · Neurobiology of Aging · doi:10.1016/j.neurobiolaging.2005.07.023 · Cited by 145
Neuromelanin and Parkinson's disease.
MARSDEN, C. D. (1983) · PubMed · Cited by 144
van der Walt, J. M., Noureddine, M., Kittappa, R., Hauser, M. A., Scott, W. K., McKay, R. D. G., Zhang, F., Stajich, J. M., Fujiwara, K., Scott, B. L., et al. (2004) · The American Journal of Human Genetics · doi:10.1086/421052 · Cited by 140
TREATMENT OF PARKINSONISM WITH BROMOCRIPTINE
Calne, D. B., Leigh, P. N., Teychenne, P. F., Bamji, A., & Greenacre, J. K. (1974) · The Lancet · doi:10.1016/s0140-6736(74)92219-3 · Cited by 138
Clinicogenetic study of PINK1 mutations in autosomal recessive early-onset parkinsonism
Li, Y., Tomiyama, H., Sato, K., Hatano, Y., Yoshino, H., Atsumi, M., Kitaguchi, M., Sasaki, S., Kawaguchi, S., Miyajima, H., et al. (2005) · Neurology · doi:10.1212/01.wnl.0000164009.36740.4e · Cited by 138
A clinical genetic study of Parkinson's disease
Lazzarini, A. M., Myers, R. H., Zimmerman, T. R., Mark, M. H., Golbe, L. I., Sage, J. I., Johnson, W. G., & Duvoisin, R. C. (1994) · Neurology · doi:10.1212/wnl.44.3_part_1.499 · Cited by 137
Dopaminergic dysfunction in unrelated, asymptomatic carriers of a single parkin mutation
Khan, N. L., Scherfler, C., Graham, E., Bhatia, K. P., Quinn, N. P., Lees, A. J., Brooks, D. J., Wood, N. W., & Piccini, P. P. (2005) · Neurology · doi:10.1212/01.wnl.0000148725.48740.6d · Cited by 132
Parkin variants in North American Parkinson's disease: Cases and controls
Lincoln, S., Maraganore, D. M., Lesnick, T. G., Bounds, R., de Andrade, M., Bower, J. H., Hardy, J., & Farrer, M. J. (2003) · Movement Disorders · doi:10.1002/mds.10601 · Cited by 131
PINK1, Parkin, and DJ-1 mutations in Italian patients with early-onset parkinsonism
Klein, C., Djarmati, A., Hedrich, K., Schäfer, N., Scaglione, C. L. M., Marchese, R., Kock, N., Schüle, B., Hiller, A., Lohnau, T., et al. (2005) · European Journal of Human Genetics · doi:10.1038/sj.ejhg.5201455 · Cited by 131
Cohort analysis of Parkinson's syndrome
Poskanzer, D. C., & Schwab, R. S. (1963) · Journal of Chronic Diseases · doi:10.1016/0021-9681(63)90098-5 · Cited by 121
Parkin-positive autosomal recessive juvenile parkinsonism with α-synuclein-positive inclusions
Sasaki, S., Shirata, A., Yamane, K., & Iwata, M. (2004) · Neurology · doi:10.1212/01.wnl.0000134657.25904.0b · Cited by 114
Gene dosage and pathogenesis of Parkinson's disease
Eriksen, J. L., Przedborski, S., & Petrucelli, L. (2005) · Trends in Molecular Medicine · doi:10.1016/j.molmed.2005.01.001 · Cited by 113
Roberts, J. W., Cora‐Locatelli, G., Bravi, D., Amantea, M., Mouradian, M. M., & Chase, T. N. (1993) · Neurology · doi:10.1212/wnl.43.12.2685 · Cited by 112
Experimenting on the Past: The Enigma of von Economo's Encephalitis Lethargica
Reid, A., McCall, S. A., Henry, J. M., & Taubenberger, J. (2001) · Journal of Neuropathology and Experimental Neurology · doi:10.1093/jnen/60.7.663 · Cited by 111
UCHL‐1 is not a Parkinson's disease susceptibility gene
Healy, D. G., Abou‐Sleiman, P. M., Casas, J. P., Ahmadi, K. R., Lynch, T., Gandhi, S., Muqit, M. M. K., Foltynie, T., Barker, R. A., Bhatia, K. P., et al. (2006) · Annals of Neurology · doi:10.1002/ana.20757 · Cited by 109
Identification of Far Upstream Element-binding Protein-1 as an Authentic Parkin Substrate
Ko, H. S., Kim, S. W., Sriram, S. R., Dawson, V. L., & Dawson, T. M. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.c600041200 · Cited by 107
PINK1 mutations in sporadic early‐onset Parkinson's disease
Tan, E., Yew, K., Chua, E., Puvan, K., Shen, H., Lee, E., Puong, K., Zhao, Y., Ratnagopal, P., Wong, M. C., et al. (2006) · Movement Disorders · doi:10.1002/mds.20810 · Cited by 105
Axonal transport of synucleins is mediated by all rate components
Jensen, P. H., Li, J., Dahlström, A. B., & Dotti, C. G. (1999) · European Journal of Neuroscience · doi:10.1046/j.1460-9568.1999.00754.x · Cited by 102
Disturbance of iron metabolism in Parkinson’s disease — ultrasonography as a biomarker
Berg, D., Hochstrasser, H., Schweitzer, K. J., & Rieß, O. (2006) · Neurotoxicity Research · doi:10.1007/bf03033302 · Cited by 101
Pathophysiology of synuclein aggregation in Lewy body disease
Mukaetova‐Ladinska, E. B., & McKeith, I. G. (2005) · Mechanisms of Ageing and Development · doi:10.1016/j.mad.2005.09.014 · Cited by 87
Subjective Complaints Precede Parkinson Disease: The Rotterdam Study
de Lau, L. M. L., Koudstaal, P. J., Albert Hofman, D., & Breteler, M. M. B. (2006) · Archives of Neurology · doi:10.1001/archneur.63.3.noc50312 · Cited by 87
Laere, K. V., Casteels, C., Ceuninck, L. D., Vanbilloen, B., Maes, A. F., Mortelmans, L. A., Vandenberghe, W., Verbruggen, A., & Dom, R. (2006) · PubMed · Cited by 86
Myllyl�, V. V., Sotaniemi, K. A., Illi, A., Suominen, K., & Ker�nen, T. (1993) · European Journal of Clinical Pharmacology · doi:10.1007/bf00315512 · Cited by 86
Lockhart, P. J., Lincoln, S., Hulihan, M., Kachergus, J., Wilkes, K., Bisceglio, G., Mash, D. C., & Farrer, M. J. (2004) · Journal of Medical Genetics · doi:10.1136/jmg.2003.011106 · Cited by 85
Alpha-synuclein haplotypes implicated in risk of Parkinson’s disease
Tan, E., Chai, A., Teo, Y., Zhao, Y., Tan, C. E., Shen, H., Chandran, V. R., Teoh, M. L., Yih, Y., Pavanni, R., et al. (2004) · Neurology · doi:10.1212/01.wnl.0000101721.25345.dc · Cited by 82
Roles of distinct cysteine residues in S-nitrosylation and dimerization of DJ-1
Ito, G., Ariga, H., Nakagawa, Y., & Iwatsubo, T. (2005) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2005.11.058 · Cited by 81
Identification of Risk and Age-at-Onset Genes on Chromosome 1p in Parkinson Disease
Oliveira, S. A., Li, Y., Noureddine, M., Zuchner, S. L., Qin, X., Pericak‐Vance, M. A., & Vance, J. M. (2005) · The American Journal of Human Genetics · doi:10.1086/432588 · Cited by 80
Clinical features and neuroimaging of PARK7‐linked parkinsonism
Dekker, M. C. J., Bonifati, V., Swieten, J. C. V., Leenders, N., Galjaard, R. H., Snijders, P. J. L. M., Horstink, M. W. I. M., Heutink, P., Oostra, B. A., & van Duijn, C. M. (2003) · Movement Disorders · doi:10.1002/mds.10422 · Cited by 74
Modification of Parkinsonism???Chronic Treatment with L-Dopa
Cotzias, G. C., Papvasiliou, P. S., & Gellene, R. A. (1969) · Journal of Occupational and Environmental Medicine · doi:10.1097/00043764-196912000-00037 · Cited by 68
Potentiation of the l-Dopa effect in man by the use of catechol-O-methyltransferase inhibitors
Ericsson, A. (1971) · Journal of the Neurological Sciences · doi:10.1016/0022-510x(71)90088-8 · Cited by 66
INHERITANCE OF THE SHAKING PALSY
ALLAN, W. (1937) · Archives of Internal Medicine · doi:10.1001/archinte.1937.00180030041003 · Cited by 63
Association Study of Parkin Gene Polymorphisms With Idiopathic Parkinson Disease
Oliveira, S. A., Scott, W. K., Nance, M., Watts, R. L., Hubble, J. P., Koller, W. C., Lyons, K. E., Pahwa, R., Stern, M. B., Hiner, B. C., et al. (2003) · Archives of Neurology · doi:10.1001/archneur.60.7.975 · Cited by 62
Gopinathan, G. V., Teräväinen, H., Dambrosia, J. M., Ward, C. D., Sanes, J. N., Stuart, W., Evarts, E. V., & Calne, D. B. (1981) · Neurology · doi:10.1212/wnl.31.4.371 · Cited by 60
Langston, J. W., Sastry, S., Chan, P., Forno, L. S., Bolin, L. M., & Monte, D. A. D. (1998) · Experimental Neurology · doi:10.1006/exnr.1998.6975 · Cited by 50
A PEDIGREE OF PARALYSIS AGITANS
Bell, J., & Clark, A. J. (1926) · Annals of Eugenics · doi:10.1111/j.1469-1809.1926.tb02046.x · Cited by 39
The parkin gene and its phenotype
Bonifati, V., Michele, G. D., L�cking, C. B., D�rr, A., Fabrizio, E., Ambrosio, G., Vanacore, N., Mari, M. D., Marconi, R., Capus, L., et al. (2001) · Neurological Sciences · doi:10.1007/s100720170042 · Cited by 35
Clinicogenetic study of PINK1 mutations in autosomal recessive early-onset parkinsonism
李, 元. (2008) · Cited by 33
Treatment of Parkinson's disease with l-DOPA and decarboxylase inhibitor
Rinne, U. K., Sonninen, V. H., & Siirtola, T. (1972) · Journal of Neurology · doi:10.1007/bf00316422 · Cited by 32
Scientific Basis for the Treatment of Parkinson's Disease
Gálvez-Jiménez, N. (2004) · Cited by 27
Neuroimaging in Parkinson’s Disease
Marek, K., Jennings, D., & Seibyl, J. P. (2003) · CRC Press eBooks · doi:10.1201/9780203912164-12 · Cited by 13
Cited by
PINK1/Parkin-mediated mitophagy is dependent on VDAC1 and p62/SQSTM1
Geisler, S., Holmström, K. M., Skujat, D., Fiesel, F. C., Rothfuss, O. C., Kahle, P. J., & Springer, W. (2010) · Nature Cell Biology · doi:10.1038/ncb2012 · Cited by 2,835
“dtd" [ ]> Parkinson's disease is the most common movement disorder and results from selective and massive loss of dopamine-containing neurons in the Substantia Nigra pars compacta (SNpc”
Multi-target-Directed Ligands To Combat Neurodegenerative Diseases
Cavalli, A., Bolognesi, M. L., Minarini, A., Rosini, M., Tumiatti, V., Recanatini, M., & Melchiorre, C. (2008) · Journal of Medicinal Chemistry · doi:10.1021/jm7009364 · Cited by 1,152
PARIS (ZNF746) Repression of PGC-1α Contributes to Neurodegeneration in Parkinson's Disease
Shin, J.-H., Ko, H. S., Kang, H., Lee, Y., Lee, Y.-I., Pletinkova, O., Troconso, J. C., Dawson, V. L., & Dawson, T. M. (2011) · Cell · doi:10.1016/j.cell.2011.02.010 · Cited by 953
Self-citationGenetic Animal Models of Parkinson's Disease
Dawson, T. M., Ko, H. S., & Dawson, V. L. (2010) · Neuron · doi:10.1016/j.neuron.2010.04.034 · Cited by 823
A review on graphene-based nanocomposites for electrochemical and fluorescent biosensors
Krishnan, S. K., Singh, E., Singh, P., Meyyappan, M., & Nalwa, H. S. (2019) · RSC Advances · doi:10.1039/c8ra09577a · Cited by 785
Metadata
- Authors
- Savitt, J. M.
- Venue
- Journal of Clinical Investigation
- Published
- 2006-07-03
- Volume
- 116
- Issue
- 7
- Pages
- 1744-1754
- ISSN
- 0021-9738 (ISSN-L)
- OpenAlex
- W1986118996
- Cited by
- 650
- References
- 124
- FWCI
- 21.96
- Type
- journal article
- Language
- en
- Open access
- bronze
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.